<DOC>
	<DOCNO>NCT00110357</DOCNO>
	<brief_summary>The purpose clinical research study establish maximum tolerate dose recommended Phase II dose Erbitux™ combination Irinotecan pediatric adolescent patient refractory solid tumor .</brief_summary>
	<brief_title>Study Erbitux™ ( Cetuximab ) Pediatric Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis solid tumor progress , follow standard therapy , standard effective therapy know . Children age 118 year . Presence active infection . Requirement receive concurrent chemotherapy immunotherapy , radiotherapy , investigational drug study . Inadequate bone marrow , hepatic , renal function .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>